Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Mr. Tad  Heitmann

Vice President of Marketing

Ms. Carolyn  McAuliffe

Senior Director of Communications

Ms. Ami  Bavishi

Director of Investor Relations

Mr. Jeffrey  Calabrese

Director of Accounting

Mr. Raj  Kannan

Chief Executive Officer & Director

Dr. David A. Hollander M.B.A., M.D.

Chief R&D Officer

Mr. John W. LaRocca Esq.

Gen. Counsel & Sec.

Dr. Casey C. Kopczynski

Co-Founder & Chief Scientific Officer

Mr. Thomas A. Mitro

Pres & Chief Operating Officer

Dr. Benjamin F. McGraw III, J.D., Pharm.D.

Executive Chairman

Läkemedelstillverkare - specialiserade och generiska

Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals, Inc. Ledningsstruktur

Information om ledningen